Actimed and Mankind Pharma Sign Exclusive Licensing Deal for Cachexia Treatments in India and South Asia

Covers exclusive rights to S-pindolol, the novel therapy in development for the treatment of cachexia, in India and South Asia Represents a major step...

November 24, 2025 | Monday | News
Thermo Fisher’s Oncomine Dx Target Test Gains FDA Approval as CDx for Bayer’s Newly Approved HYRNUO™

  Test will serve as a companion diagnostic for Bayer’s HYRNUO™ (sevabertinib) to identify patients with NSCLC eligible for HER2-targeted...

November 20, 2025 | Thursday | News
BriaPro Launches AI-Driven Collaboration With Receptor.AI to Design Isoform-Selective Anti-Cancer Kinase Inhibitors

Collaboration uses Receptor AI's platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, a BriaCell subsidiary Partners...

November 21, 2025 | Friday | News
Psyence BioMed Secures Sustainable, GMP-Compliant Iboga Supply Through PsyLabs to Advance Ibogaine Clinical Development

Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived p...

November 21, 2025 | Friday | News
Dexcom Receives FDA Clearance for Smart Basal, a First-of-Its-Kind AI-Powered Basal Insulin Dosing Solution

-DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-int...

November 20, 2025 | Thursday | News
Profluent Raises $106M to Accelerate Frontier AI for Programmable Biology

Profluent, a leader in frontier AI for protein design,  announced a $106 million financing co-led by Altimeter Capital and Bezos Expeditions, with p...

November 20, 2025 | Thursday | News
PrognomiQ Launches ProVue Lung, a Blood-Based Test Designed for Earlier Lung Cancer Detection

Initial commercial availability begins through an Early Experience Program with Penn Highlands Healthcare and Allegheny Health Network –  Pr...

November 19, 2025 | Wednesday | News
Ankyra Therapeutics Doses First Patient in Phase 1b LANTERN Trial Evaluating Tolododekin Alfa With PD-1/PD-L1 Checkpoint Inhibitors in NSCLC

Phase 1b LANTERN clinical study is assessing tolododekin alfa, anchored IL-12 immunotherapy, in combination with anti PD-1/PD-L1 immune checkpoint bl...

November 18, 2025 | Tuesday | News
Scotland Strengthens Position as Global Brain Health Innovator With New Alzheimer’s Research Centre in Aberdeen

Aberdeen clinical research centre widens access to clinical trials across Scotland, advancing early Alzheimer’s research ONE BioHub provides Scott...

November 18, 2025 | Tuesday | News
Thermo Fisher Secures FDA Clearance for First-of-Its-Kind Automated System to Transform Multiple Myeloma Diagnosis

First-of-its-kind, automated system delivers increased sensitivity, specific identification of disease markers and improved laboratory workflow to suppor...

November 13, 2025 | Thursday | Regulatory
LISCure Biosciences Initiates Global Phase 2 Trial of LB-P8 in Primary Sclerosing Cholangitis

 LISCure Biosciences ("LISCure"), a clinical-stage biopharmaceutical company, announced the initiation of patient dosing in a global Phase 2 cl...

November 11, 2025 | Tuesday | News
Nurami Medical Advances Artifix® Toward First-in-Human Trials With Successful Phase 1 Completion

Nurami Medical, a company developing next-generation regenerative solutions for soft tissue repair, has announced successful completion of Phase 1 of...

November 11, 2025 | Tuesday | News
Vascarta and CUNY Report Preclinical Breakthrough Demonstrating STO-1 Selectively Eliminates Glioblastoma Cells

Vascarta Inc., a healthspan focused, clinical stage biopharmaceutical company advancing safe, patient friendly therapies for pain, inflammation, and, in ...

November 11, 2025 | Tuesday | News
SanegeneBio and Eli Lilly Announce Global Collaboration on RNAi Therapies for Metabolic Diseases

  SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collab...

November 10, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close